Clinical trials of R-(-)-gossypol (AT-101) in newly diagnosed and recurrent glioblastoma: NABTT 0602 and NABTT 0702
Fig 1
Treatment schemas for NABTT 0602 arm I and arm II.
In arm I AT-101 was given five days per week during RT and concurrent with temozolomide for six weeks. In arm II enrollment and treatment with AT-101 started four weeks after completion of RT. AT-101 was administered concurrently with each adjuvant cycle of temozolomide.